Full-Time

Clinical Document Control Specialist

Posted on 4/4/2025

PROCEPT BioRobotics

PROCEPT BioRobotics

501-1,000 employees

Develops robotic solutions for BPH treatment

Compensation Overview

$82k - $95k/yr

+ Bonus + Equity/RSUs

Mid, Senior

No H1B Sponsorship

Remote in USA

Candidates must be based in the USA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a PROCEPT BioRobotics referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor's degree in life sciences, regulatory affairs, Clinical operations or a related field.
  • 2-5 years of experience in document control, clinical research, or regulatory compliance within the medical device or pharmaceutical industry.
  • Knowledge of GCP, FDA regulations (e.g., 21 CFR Part 11), EU MDR, and ISO 14155 standards.
  • Strong attention to detail and organizational skills.
  • Proficiency in electronic document management systems and Microsoft Office Suite.
  • Excellent written and verbal communication skills.
  • Ability to work independently and manage multiple tasks simultaneously.
Responsibilities
  • Create, organize, and maintain clinical trial master files (TMFs) and other essential clinical documentation.
  • Ensure all clinical documents are complete, accurate, and compliant with Good Clinical Practice (GCP) and regulatory requirements (e.g., FDA, ISO 14155, MDR).
  • Manage version control and track document revisions to ensure all stakeholders have access to the latest versions.
  • Ensure all clinical documents meet regulatory and quality standards for submission to governing bodies.
  • Support internal and external audits by providing organized, comprehensive documentation.
  • Develop, implement, and improve document control processes to enhance efficiency and accuracy.
  • Train clinical team members on document control procedures and best practices.
  • Oversee the archiving of clinical documents.
  • Ensure timely and efficient retrieval of documents for inspections, audits, or project needs.
  • Maintain and manage electronic document management systems (EDMS) or clinical trial software tools when utilized.
  • Ensure system access controls and confidentiality of sensitive data.
Desired Qualifications
  • Certification in Clinical Research or Regulatory Affairs (e.g., ACRP, RAPS).
  • Familiarity with clinical trial management systems (CTMS).

PROCEPT BioRobotics develops robotic solutions specifically for treating benign prostatic hyperplasia (BPH), a condition that affects many older men by causing prostate enlargement and urinary issues. Their main product, the AquaBeam Robotic System, utilizes Aquablation therapy, which combines real-time imaging, robotics, and waterjet technology to precisely remove prostate tissue in a minimally invasive manner. This system is designed for urologists and healthcare facilities, allowing for improved patient outcomes and more efficient surgical procedures. Unlike competitors, PROCEPT BioRobotics focuses on providing predictable results and reducing complications, which has led to their technology being recognized in clinical practice guidelines. The company's goal is to enhance the quality of life for patients suffering from BPH through advanced surgical solutions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval for Aquablation therapy in prostate cancer suggests expansion opportunities.
  • Significant investment in robotics highlights a robust funding environment for PROCEPT.
  • Long-term data confirms Aquablation therapy's efficacy, driving further clinical adoption.

What critics are saying

  • HYDROS™ Robotic System poses a competitive threat with advanced features.
  • Established companies like Intuitive Surgical challenge PROCEPT's market position.
  • Continuous R&D investment is needed to maintain technological leadership.

What makes PROCEPT BioRobotics unique

  • AquaBeam Robotic System offers minimally invasive BPH treatment with high precision.
  • Aquablation therapy provides effective outcomes regardless of prostate size or surgeon experience.
  • Over 100 peer-reviewed publications support the clinical advantages of Aquablation therapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Parental Leave

Paid Holidays

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 1%

2 year growth

↑ 3%
Stock Titan
Mar 14th, 2025
PROCEPT BioRobotics(R) Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) - PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time.

Hit Consultant
Jan 27th, 2025
Mount Sinai Performs Nyc’S First Enlarged Prostate Procedure With Hydros™ Robotic System

What You Should Know:– The Mount Sinai Hospital has achieved a significant milestone in men’s health by performing New York City’s first procedures using the HYDROS™ Robotic System.– The technology offers a minimally invasive treatment option for benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.Impact of BPHBPH is a prevalent condition affecting millions of men, particularly those over 60. While non-cancerous, BPH can significantly impact quality of life, causing urinary symptoms such as frequent urination, weak stream, and nighttime urgency.Minimally Invasive Procedure Offers Hope for Men with BPHThe HYDROS™ system represents a major advancement in BPH treatment, building upon traditional methods like transurethral resection of the prostate (TURP) and laser treatments. It offers several key innovations:AI-Powered Treatment Planning: The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy.The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy. Advanced Visualization: HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning.HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning. Robotic-Assisted Waterjet Resection: The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction.The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction. Streamlined Workflow: HYDROS™ features an integrated tower for efficient setup, an adjustable touchscreen for improved ergonomics, and user-friendly software to guide surgeons through the procedure.Early Success and Expanding AccessMount Sinai urologists have successfully performed the health system’s first three HYDROS™ procedures, with all patients responding well and being discharged the following day

The Robot Report
Jan 6th, 2025
Robotics Investments Top $7.4B In October 2024

Robotics investments topped $7.4 billion for the month of October 2024, the result of 77 funding rounds. The investment total was led by Waymo’s $5.6 billion raise, which is the largest single round of the year through November. October’s total was the largest through the first 10 months of the year. The previous monthly high was the $3.7 billion raised in September 2024. The total investment for the period of January through October 2024 was more than $20 billion. Developers of autonomous driving technologies once again dominated the list of largest investments for the month

Bizjournals
Oct 29th, 2024
Biotech firm announces $175M public stock offering

Procept BioRobotics announce a $175 million public stock offering, along with successful Q3 earnings.

MarketBeat
Aug 14th, 2024
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?

PROCEPT BioRobotics operates in the medical sector and competes with medical robot and device makers like Intuitive Surgical, Medtronic PLC NYSE: MDT, and Zimmer Biomet Holdings NYSE: ZBH.

INACTIVE